Timing of elective surgery and risk assessment after SARS-CoV-2 infection: an update: A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Centre for Perioperative Care, Federation of Surgical Specialty Associations, Royal College of Anaesthetists, Royal College of Surgeons of England.
COVID-19
SARS-CoV-2
complications
surgery
timing
Journal
Anaesthesia
ISSN: 1365-2044
Titre abrégé: Anaesthesia
Pays: England
ID NLM: 0370524
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
accepted:
08
02
2022
pubmed:
24
2
2022
medline:
4
8
2022
entrez:
23
2
2022
Statut:
ppublish
Résumé
The impact of vaccination and new SARS-CoV-2 variants on peri-operative outcomes is unclear. We aimed to update previously published consensus recommendations on timing of elective surgery after SARS-CoV-2 infection to assist policymakers, administrative staff, clinicians and patients. The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting. We recommend individualised multidisciplinary risk assessment for patients requiring elective surgery within 7 weeks of SARS-CoV-2 infection. This should include baseline mortality risk calculation and assessment of risk modifiers (patient factors; SARS-CoV-2 infection; surgical factors). Asymptomatic SARS-CoV-2 infection with previous variants increased peri-operative mortality risk three-fold throughout the 6 weeks after infection, and assumptions that asymptomatic or mildly symptomatic omicron SARS-CoV-2 infection does not add risk are currently unfounded. Patients with persistent symptoms and those with moderate-to-severe COVID-19 may require a longer delay than 7 weeks. Elective surgery should not take place within 10 days of diagnosis of SARS-CoV-2 infection, predominantly because the patient may be infectious, which is a risk to surgical pathways, staff and other patients. We now emphasise that timing of surgery should include the assessment of baseline and increased risk, optimising vaccination and functional status, and shared decision-making. While these recommendations focus on the omicron variant and current evidence, the principles may also be of relevance to future variants. As further data emerge, these recommendations may be revised.
Identifiants
pubmed: 35194788
doi: 10.1111/anae.15699
pmc: PMC9111236
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
580-587Informations de copyright
© 2022 The Authors. Anaesthesia published by John Wiley & Sons Ltd on behalf of Association of Anaesthetists.
Références
Br J Surg. 2021 Sep 27;108(9):1056-1063
pubmed: 33761533
Anaesthesia. 2020 Nov;75(11):1494-1508
pubmed: 32677708
Lancet. 2020 May 2;395(10234):1418-1420
pubmed: 32305073
J Clin Oncol. 2021 Jan 1;39(1):66-78
pubmed: 33021869
Anaesthesia. 2021 Nov;76(11):1454-1464
pubmed: 34371522
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Br J Surg. 2020 Oct;107(11):1440-1449
pubmed: 32395848
Br J Anaesth. 2021 Aug;127(2):205-214
pubmed: 34148733
Anaesthesia. 2021 Jul;76(7):940-946
pubmed: 33735942
Anaesthesia. 2022 Jan;77(1):28-39
pubmed: 34428858
JAMA Surg. 2022 Mar 1;157(3):187-188
pubmed: 35019990
Anaesthesia. 2021 Jun;76(6):748-758
pubmed: 33690889
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
Lancet. 2022 Jan 15;399(10321):233-234
pubmed: 34922640